GlassScriptPhysician profile
Amy Gallagher
NPI 1134674690
$3,786.90
in general payments reported to CMS, 2019-2025
45 companies · $86.62 in 2025
The $86.62 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $809 · 2023: $1,420 · 2024: $1,299 · 2025: $86.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.21 |
| Education | $473.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $458.65 | 2021-2024 | Darzalex, Imbruvica, Erleada |
| Incyte Corporation | $337.56 | 2022-2024 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $305.40 | 2023-2024 | |
| Celgene Corporation | $262.38 | 2022-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $238.70 | 2022-2024 | Lynparza, Imfinzi, Enhertu |
| Eisai INC. | $225.10 | 2022-2024 | |
| Seagen INC. | $201.75 | 2023 | Padcev, Tukysa, Tivdak |
| Abbvie INC. | $184.43 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $122.32 | 2022-2023 | Imbruvica |
| Sobi, INC | $115.16 | 2024 | |
| Gilead Sciences, INC. | $112.71 | 2022-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $89.19 | 2022-2025 | Zejula, Jemperli |
| Genzyme Corporation | $84.81 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $79.47 | 2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $69.80 | 2023-2025 | Enhertu, Injectafer |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.